Meet an IBDIQ contributor /

Adam S. Faye, MD, MS

About Adam S. Faye, MD, MS

Adam S. Faye, MD, MS, is an assistant professor of medicine & population health in the Division of Gastroenterology at New York University Grossman School of Medicine. Dr. Faye completed his undergraduate degree in biochemistry at Harvard University and medical school degree at Weill Cornell Medical College, receiving a number of awards for his academic achievements. He completed his internal medicine training, chief year, and gastroenterology fellowship training at Columbia University Medical Center. During his gastroenterology fellowship, Dr. Faye also completed a master’s degree in biostatistics at the Columbia Mailman School of Public Health, and pursued an additional year of advanced inflammatory bowel disease (IBD) training at the Icahn School of Medicine at Mount Sinai.

Dr. Faye’s research interest is focused at the intersection of geriatrics and gastroenterology. His specific focus area centers around understanding how biological measures such as frailty and sarcopenia can be used to improve both risk stratification tools and clinical outcomes among older adults with inflammatory bowel disease. He has received funding from the National Institutes of Health (NIH)/National Institute on Aging (NIA), American College of Gastroenterology (ACG), and the Crohn’s & Colitis Foundation to advance this work. Dr. Faye is also the co-chair of the NIA-funded Clin-STAR Frailty & Inflammation Groups, Geriatrics Section Editor for Current Treatment Options in Gastroenterology, a member of both the ACG Educational Affairs & Research Committees, a member of Rising Educators Academics and Clinicians Helping IBD (REACH-IBD), a member of the American Gastroenterological Association Young Delegates Program, and was selected for the 2022 Advances in IBD Ambassador Program, 2022 ACG Early Career Leaders Program, 2023 NIA Butler-Williams Scholar Program, and 2024 ACG Institute Clinical Research Leadership Program. He has published extensively in this area (including the top Gut article for 2023), reviewed for many of the top GI journals, and been invited to speak both nationally and internationally on his research.


  • Consultant/Advisory Board: Takeda, BMS, AbbVie, Douglas Pharmaceuticals